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Antisense Masking of an hnRNP A1/A2
Intronic Splicing Silencer
Corrects SMN2 Splicing in Transgenic Mice
Yimin Hua,1 Timothy A. Vickers,2 Hazeem L. Okunola,1 C. Frank Bennett,2 and Adrian R. Krainer1,*
survival of motor neuron 2, centromeric (SMN2) is a gene that modiﬁes the severity of spinal muscular atrophy (SMA), a motor-neuron dis-
ease that is the leading genetic cause of infant mortality. Increasing inclusion of SMN2 exon 7, which is predominantly skipped, holds
promise to treat or possibly cure SMA; one practical strategy is the disruption of splicing silencers that impair exon 7 recognition.
By using an antisense oligonucleotide (ASO)-tiling method, we systematically screened the proximal intronic regions ﬂanking exon
7 and identiﬁed two intronic splicing silencers (ISSs): one in intron 6 and a recently described one in intron 7. We analyzed the intron
7 ISS by mutagenesis, coupled with splicing assays, RNA-afﬁnity chromatography, and protein overexpression, and found two tandem
hnRNP A1/A2 motifs within the ISS that are responsible for its inhibitory character. Mutations in these two motifs, or ASOs that block
them, promote very efﬁcient exon 7 inclusion.We screened 31 ASOs in this region and selected two optimal ones to test in human SMN2
transgenic mice. Both ASOs strongly increased hSMN2 exon 7 inclusion in the liver and kidney of the transgenic animals. Our results
show that the high-resolution ASO-tiling approach can identify cis-elements that modulate splicing positively or negatively. Most
importantly, our results highlight the therapeutic potential of some of these ASOs in the context of SMA.Introduction
Premessenger RNA (pre-mRNA) splicing is catalyzed by
the spliceosome, a large dynamic ribonucleoprotein com-
plex.1–3 Splicing involves several stepwise assembly and
catalytic processes, including exon and intron recogni-
tion, excision of intervening introns, and exon joining.
Generally, splicing signals at or near the exon-intron junc-
tions of pre-mRNA, including the 50 splice site, 30 splice
site, polypyrimidine tract, and branchpoint sequence,
are necessary but not sufﬁcient for accurate and efﬁcient
exon recognition by the spliceosome. Additional positive
signals in an exon and/or its ﬂanking introns are also
required for efﬁcient exon recognition, particularly when
the exon is alternatively spliced or is constitutively spliced
but has weak splice sites.4 These positive cis-elements,
including exonic splicing enhancers (ESEs) and intronic
splicing enhancers (ISEs), are generally binding sites for
splicing activators, such as serine-arginine-rich (SR) pro-
teins, or may adopt favorable secondary structures. ESEs
and ISEs can counteract negative cis-elements, such as ex-
onic splicing silencers (ESSs) and intronic splicing silencers
(ISSs), which generally are the binding sites for splicing
repressors, such as certain hnRNP proteins, or adopt unfa-
vorable higher-order structures. The antagonism between
SR proteins and hnRNP proteins is one mechanism by
which splicing is ﬁnely tuned.5 Disruption of cis-elements,
inducing exon skipping, such as in the survival of motor
neuron 2, centromeric (SMN2) gene (MIM 601627), or tilting
the ratio of different mRNA isoforms derived from a single
gene, such as the MAPT (microtubule-associated protein tau)
gene (MIM 137140) in frontotemporal dementia (MIM
600274), can lead to severe diseases.4,6–11834 The American Journal of Human Genetics 82, 834–848, April 20SMN2 is a modifying gene in spinal muscular atrophy
(SMA types I, II, and III [MIMs 253300, 253550, and
253400]), which is caused by loss-of-function mutations
or deletions of the closely related survival of motor neuron
1, telomeric (SMN1) gene (MIM 600354).12 Both genes
encode identical SMN proteins; however, only SMN1 gen-
erates full-length mRNA and protein (UniProt accession
number Q16637-1) as predominant products. The major-
ity of SMN2 mRNA lacks exon 7 because of a C6T transi-
tion in SMN2 exon 7 (relative to SMN1) that affects exon
recognition during splicing, resulting in a defective exon
7 skipped protein isoform (UniProt accession number
Q16637-3).13,14 Recently, an A100G transition in SMN2
intron 7 (relative to SMN1) has also been reported to par-
tially contribute to the predominant skipping of SMN2
exon 7.15
The SMN protein, together with several Gemin proteins,
forms an SMN complex that functions as a chaperone to fa-
cilitate assembly of U snRNPs and possibly other RNPs.16,17
SMNmay have additional roles in assisting arginine meth-
ylation of some splicing-related proteins18 and transport-
ing axonal mRNAs in motor neurons.19 The 54-nt-long
alternatively spliced exon 7 encodes a C-terminal peptide
of 16 amino acids, which is essential for SMN protein
stability and proper cytoplasmic localization, and possibly
comprises a motif that plays speciﬁc functions in main-
taining growth cones in motor neurons.20–24
Exon 7 in SMN1 and SMN2 has a weak 50 splice site,
reﬂecting its divergence from the consensus sequence
and a stem-loop structure at the exon 7-intron 7 junction
that interferes with U1 small nuclear RNA (snRNA) base
pairing to the 50 splice site.25 The drastic difference
in exon 7 inclusion between these two genes and the1Cold Spring Harbor Laboratory, PO Box 100, Cold Spring Harbor, NY 11724, USA; 2Isis Pharmaceuticals, 1896 Rutherford Road, Carlsbad, CA 92008, USA
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involvement of multiple cis-elements and trans-factors are
indicative of the complex regulatory interplay between
various splicing signals. For both genes, a Tra2-b1 (Uniprot
accession number P62995-1) motif in the central region of
exon 7 is crucial in promoting inclusion of the exon.26
It appears that the central element is recognized by a splic-
ing-activating protein complex that includes at least Tra2-
b1, SRp30c (UniProt accession number Q13242), and
hnRNP G (UniProt accession number P38159).27,28 Inter-
estingly, antagonism between Tra2-b1 and hnRNP G has
been proposed to regulate other alternatively spliced
exons.29 We predicted the existence of another ESE motif
in the central region (þ28 to þ34) that might bind to an-
other trans-acting protein essential for the central-core pro-
tein complex, because antisense oligonucleotides (ASOs)
binding to this region potently inhibit exon 7 inclusion.30
In SMN1, anSF2/ASF (UniProt accessionnumberQ07955)
motifnear the30 splice site (þ6 toþ12) serves as anothercru-
cial ESE, which is absent or weakened in the SMN2 gene
because of the C6T transition, accounting for the predomi-
nant skipping of SMN2 exon 7.6,7 In addition, an ISE in
intron 7 (þ56 to þ79) that comprises a potential stem-
loop structure has been characterized in the context of an
exon-trapping vector.31
On the other hand, several ESSs and ISSs contribute
to the repression of exon 7 splicing. In SMN2, the C6T
change, which abrogates the SF2/ASF binding site, has
also been purported to create an hnRNPA1 (UniProt acces-
sion number P09651-2) motif.7,32,33 We recently identiﬁed
two inhibitory regions, A (þ4 to þ21) and B (þ34 to þ51)
in SMN2 exon 7,30 which is consistent with a previous
SELEX study pointing to a conserved track in the middle
of SMN2 exon 7 ﬂanked on both sides by inhibitory
sequences.34 Because for both SMN genes the majority of
ASOs binding to these two regions promote exon 7 inclu-
sion, it appears that the net effect of region A is also inhib-
itory, even in SMN1, in spite of the presence of the SF2/ASF
site (þ6 to þ12). Region B and its downstream 50 splice site
comprise the above-mentioned inhibitory stem-loop struc-
ture that hinders U1 binding to the 50 splice site of intron
7.25 Moreover, two ISSs with unknown mechanisms of ac-
tion were reported earlier: One, in intron 6 (75 to 89),
named element 1, was identiﬁed in the context of an
exon-trapping vector and an SMN2 minigene;35 the other
one, in intron 7 (þ10 to þ24), named N1, is a potent
ISS.36 Finally, the A100G transition in SMN2 intron 7 was
recently reported to create another hnRNP A1 binding
site, exacerbating the repression of exon 7 splicing caused
by the C6T change.15
cis-elements are useful targets for deliberatemanipulation
of pre-mRNA splicing with antisense molecules. For exam-
ple, splice sites, ESEs, and ISEs are ideal ASO targets for pro-
motion of exon skipping; this strategy has been employed,
e.g., in the development of a treatment for Duchenne mus-
cular dystrophy.37,38On theotherhand, ESSs and ISSs repre-
sent ideal ASO targets for promotion of exon inclusion. Re-
cently, we screened the entire SMN2 exon 7 by tiling ASOs,Thefollowed by a higher-resolution ASO walk through two
promising regions; we identiﬁed two putative ESSs and cor-
responding ASOs with therapeutic potential for SMA.30
In this study, we applied a similar ASO-tiling method to
search for inhibitory cis-acting elements residing in the
ﬂanking intron sequences, within 60 nt on each side of
exon 7. With the ﬁrst coarse ASO walk, we identiﬁed two
ISSs: a new one in intron 6 and one in intron 7 that corre-
sponds to a recently reported ISS.36With the secondary mi-
crowalk,weoptimizedASOswithdifferent lengths.Byusing
several assays,wediscovered that the intron7 ISS consists of
two weak hnRNPA1 or hnRNPA2 (UniProt accession num-
ber P22626-2)motifs, which, working together, strongly in-
hibit exon 7 inclusion in the SMN2 context. Moreover, on
the basis of our results in cell-free extracts and in cultured
cells, we further tested selected ASOs that abrogate the in-
tron 7 ISS in hSMN2 transgenic mice, hemizygote or wild-
type (WT) at the mouse Smn locus. We demonstrate that
these ASOs strongly promote exon 7 inclusion in the trans-
gene mRNA in liver, after intravenous administration. Our
results show that the high-resolution ASO-tiling approach
can identify exonic and intronic elements or structures
that modulate splicing positively or negatively. Further-
more, they highlight the therapeutic potential of some of
these ASOs in the context of SMA, provided that they
can be effectively delivered to the central nervous system
(CNS).
Material and Methods
Oligonucleotide Synthesis
Synthesis and puriﬁcation of chimeric 20-O-methoxyethyl-modi-
ﬁed oligonucleotides with phosphodiester or phosphorothioate
backbone were performed with an Applied Biosystems 380B auto-
mated DNA synthesizer as described.39 The oligonucleotides with
phosphodiester backbone for experiments in cell culture were dis-
solved in water, and the ones with phosphorothioate backbone for
experiments in mice were dissolved in saline. The sequences of all
the oligonucleotides are shown in Table 1.
Constructs
SMN minigene constructs were pCI-SMN1, pCI-SMN2, pEGFP-
SMN1, and pEGFP-SMN2, as described.30 In brief, the two mini-
genes comprise the 111 nt exon 6, a 200 nt shortened intron
6, the 54 nt exon 7, the 444 nt intron 7, and the ﬁrst 75 nt of
exon 8. A consensus 50 splice site was placed at the 30 end of
exon 8 in pCI-SMN1 and pCI-SMN2 for the enhancement
of exon 7 splicing in vitro. Out of the total four nucleotide differ-
ences in these regions that occur naturally between endogenous
SMN1 and SMN2, two were carried over to the two minigenes,
C6T in exon 7 and G44A in intron 6 (which is part of the region
we targeted with an ASO walk), but not A100G and A215G in in-
tron 7, which until recently were thought to play no role in SMN2
exon 7 skipping;13,14 note that a more recent study reported a
contribution of the intron 7 A100G change to the repression of
SMN2 exon 7 inclusion.15 Plasmid pCGT7-A1 was generated previ-
ously.40 hnRNP A2 complementary DNA (cDNA) was ampliﬁed
with a set of primers, NheI-F (50-CCGCTAGCGAGAGAGAAAAGGAmerican Journal of Human Genetics 82, 834–848, April 2008 835
Table 1. MOE ASOs Used in the Two-Step Intron Walks
ASO Walk ASO # ASO Sequence Target
Initial Walk in Intron 6a
15–01 50-CTGTAAGGAAAATAA-30 1 to 15
20–06 50-AGGAAAATAAAGGAA-30 6 to 20
25–11 50-AATAAAGGAAGTTAA-30 11 to 25
30–16 50-AGGAAGTTAAAAAAA-30 16 to 30
35–21 50-GTTAAAAAAAATAGC-30 21 to 35
40–26 50-AAAAAATAGCTATAT-30 26 to 40
45–31 50-ATAGCTATATAGATA-30 31 to 45
50–36 50-TATATAGATATAGAT-30 36 to 50
55–41 50-AGATATAGATAGCTA-30 41 to 55
60–46 50-TAGATAGCTATATAT-30 46 to 60
Initial Walk in Intron 7a
01–15 50-TGCTGGCAGACTTAC-30 1 to 15
06–20 50-CATAATGCTGGCAGA-30 6 to 20
11–25 50-ACTTTCATAATGCTG-30 11 to 25
16–30 50-GATTCACTTTCATAA-30 16 to 30
21–35 50-AGTAAGATTCACTTT-30 21 to 35
26–40 50-ACAAAAGTAAGATTC-30 26 to 40
31–45 50-GTTTTACAAAAGTAA-30 31 to 45
36–50 50-ATAAAGTTTTACAAA-30 36 to 50
41–55 50-AAACCATAAAGTTTT-30 41 to 55
46–60 50-TCCACAAACCATAAA-30 46 to 60
Microwalk in Intron 6a
51–37 50-ATATAGATATAGATA-30 37 to 51
52–38 50-TATAGATATAGATAG-30 38 to 52
53–39 50-ATAGATATAGATAGC-30 39 to 53
54–40 50-TAGATATAGATAGCT-30 40 to 54
56–42 50-GATATAGATAGCTAT-30 42 to 56
57–43 50-ATATAGATAGCTATA-30 43 to 57
58–44 50-TATAGATAGCTATAT-30 44 to 58
59–45 50-ATAGATAGCTATATA-30 45 to 59
48–37 50-ATATAGATATAG-30 37 to 48
49–38 50-TATAGATATAGA-30 38 to 49
50–39 50-ATAGATATAGAT-30 39 to 50
51–40 50-TAGATATAGATA-30 40 to 51
52–41 50-AGATATAGATAG-30 41 to 52
53–42 50-GATATAGATAGC-30 42 to 53
54–43 50-ATATAGATAGCT-30 43 to 54
55–44 50-TATAGATAGCTA-30 44 to 55
56–45 50-ATAGATAGCTAT-30 45 to 56
Microwalk in Intron 7a
08–25 50-ACTTTCATAATGCTGGCA-30 8 to 25
09–26 50-CACTTTCATAATGCTGGC-30 9 to 26
10–27 50-TCACTTTCATAATGCTGG-30 10 to 27
11–28 50-TTCACTTTCATAATGCTG-30 11 to 28
15–29 50-ATTCACTTTCATAAT-30 15 to 29
14–28 50-TTCACTTTCATAATG-30 14 to 28
13–27 50-TCACTTTCATAATGC-30 13 to 27
12–26 50-CACTTTCATAATGCT-30 12 to 26
10–24 50-CTTTCATAATGCTGG-30 10 to 24
09–23 50-TTTCATAATGCTGGC-30 9 to 23
08–22 50-TTCATAATGCTGGCA-30 8 to 22
07–21 50-TCATAATGCTGGCAG-30 7 to 21
18–29 50-ATTCACTTTCAT-30 18 to 29
17–28 50-TTCACTTTCATA-30 17 to 28
16–27 50-TCACTTTCATAA-30 16 to 27
15–26 50-CACTTTCATAAT-30 15 to 26
14–25 50-ACTTTCATAATG-30 14 to 25
13–24 50-CTTTCATAATGC-30 13 to 24
12–23 50-TTTCATAATGCT-30 12 to 23836 The American Journal of Human Genetics 82, 834–848, April 20AACAGTTC-30) and BclI-R (50-GATGATCAGTATCGGCTCCTCCC
AC-30), digested with NheI and BclI, and subcloned into the
XbaI-BamHI sites of pCGT7-A1.
In Vitro Splicing
Plasmids pCI-SMN1 and pCI-SMN2 were linearized with SalI and
then used for in vitro transcription with T7 RNA polymerase
(Promega) in the presence of a-32P-UTP and 7Me-GpppG cap ana-
log for the generation of in vitro splicing substrates, which were
puriﬁed by denaturing polyacrylamide gel electrophoresis (PAGE)
and spliced in HeLa cell nuclear extract, as described.6,30,41,42 In
brief, we incubated 8 fmol transcript in 10 ml splicing reactions
containing 3 ml nuclear extract and 1.6 mM MgCl2 at 37
C for
3.5 hr. RNA was then extracted and separated by 8% denaturing
PAGE, and phosphorimage analysis with an Image Reader FLA-
5100 (FujiFilm Medical Systems) followed. The extent of exon 7
inclusion was calculated as a percentage of the total amount of
spliced mRNA. The signal intensity of each mRNA isoform band
was normalized according to its U content.
Cell Culture and Transfection
HEK293 cells, SMA type I homozygous and carrier ﬁbroblasts
(3813 and 3814, Coriell Cell Repositories) were cultured in Dulbec-
co’s modiﬁed Eagle’s medium (DMEM, Invitrogen) containing
10% (v/v) fetal bovine serum and antibiotics (100 U/ml penicillin
and 100 mg/ml streptomycin). For transfection ofMOE oligonucle-
otides and plasmids into HEK293 cells, electroporation was carried
out as described, and puromycin selection followed.30 For trans-
fection of MOE oligonucleotides into 3813 cells, Lipofectin (Invi-
trogen) was used according to the manufacturer’s instructions.
RT-PCR
The reverse transcriptase-polymerase chain reaction (RT-PCR)
primers and procedures for the ampliﬁcation of transcripts derived
from all of theminigene constructs, or from the endogenous SMN1
and SMN2 genes, were as described.30 A pair of human-speciﬁc
primers was used for the ampliﬁcation of human SMN2 transcripts
in RNA samples from transgenic mouse tissues: E4-33to55-F (50-
AAGTGAGAACTCCAGGTCTCCTG-30) and E8-15to36-R (50-
GTGGTGTCATTTAGTGCTGCTC-30). PCR products from the tran-
scripts of endogenous SMN1 and SMN2 genes were digested with
DdeI so that SMN1 and SMN2 cDNAs could be separated, as de-
scribed.30 All PCR products were labeled with a-32P-dCTP and ana-
lyzed by 6% or 8% native PAGE, and phosphorimage analysis fol-
lowed. The extent of exon 7 inclusion was calculated as
described,30 and the signal intensity of each cDNA band was nor-
malized according to its GþC content.
Table 1. Continued
11–22 50-TTCATAATGCTG-30 11 to 22
10–21 50-TCATAATGCTGG-30 10 to 21
Control Oligonucleotideb
00–00 50-TGCATCTCATTGTAG-30 None
a Each ASO designation corresponds to the 50 and 30 nucleotide numbers of
the intron sense sequence to which the ASO is complementary.
b The sequence of the control ASO is unrelated to SMN2 exon 7 or to introns
6 and 7.08
RNA-Afﬁnity Chromatography
RNA-afﬁnity chromatography was performed as described.7,43
RNA oligonucleotides WT (50-CCAGCATTATGAAAGT-30), A12C
(50-CCCGCATTATGAAAGT-30), A23C (50-CCAGCATTATGAACG
T-30), and 2A-2C (50-CCCGCATTATGAACGT-30) were purchased
from Integrated DNA Technologies (Coralville, IA). Sixty micro-
grams of each RNA was oxidized with sodium m-periodate in a
24 ml reaction and then mixed with 100 ml (1:1 slurry) of adipic-
acid-dihydrazide agarose beads (Sigma) by rotation overnight
at 4C. A 250 ml in vitro splicing reaction mix including 100 ml
of HeLa nuclear extract was added to 50 ml of RNA-bound beads
equilibrated with buffer D containing 0.1MKCl.Mixtures were in-
cubated at 30C for 40min and divided into two aliquots for wash-
ing three times with buffer D containing either 150 mM or
300 mM KCl. After the ﬁnal wash, the beads were resuspended
in 50 ml of 13 Laemmli buffer and heated at 100C for 5 min for
the elution of bound proteins. Twelve microliters of each protein
sample was loaded on a 12% sodium dodecyl sulfate (SDS) poly-
acrylamide gel for Coomassie-Blue staining, and 1 ml was loaded
for western blotting.
Western Blotting
Protein samples separated by 12% SDS-PAGE were electroblotted
onto nitrocellulose membranes. The blots were then probed
with monoclonal antibodies anti-hnRNP A/B family (A1/UP1-
62), anti-hnRNP A1 (A1/UP1-55), anti-hnRNP A2/B1 (DP3B3;
Abcam), anti-T7 (T7-Tag, Novagen), anti-SMN (BD Transduction
Laboratories) or anti-a-tubulin (Sigma), followed by horseradish-
peroxidase-conjugated goat anti-mouse secondary antibody
(Pierce). Protein signals were detected with Lumi-Light Western
Blotting Substrate (Roche Diagnostics).
Administration of Oligonucleotides
to hSMN2 Transgenic Mice
All mouse experiments were performed according to protocols ap-
proved by Cold Spring Harbor Laboratory. Thirty-two adult hu-
man SMN2 transgenic mice, male or female, hemizygote or WT
at the mouse Smn locus, were tested. ASOs, dissolved in 0.9% sa-
line solution, were injected through the tail vein at a dose of 25
mg/kg, twice a week for every mouse. Mice 1–8 were injected
with saline alone; mice 9–16 were injected with control ASO 00–
00; mice 17–24 were injected with 15-mer ASO 09–23, and mice
25–32 were injected with 18-mer ASO 10–27. Mice 1, 2, 9, 10,
17, 18, 25, and 26 were sacriﬁced after 1 week; mice 3, 4, 11, 12,
19, 20, 27, and 28 were sacriﬁced after 2 weeks; mice 5, 6, 13,
14, 21, 22, 29, and 30 were sacriﬁced after 3 weeks; and mice 7,
8, 15, 16, 23, 24, 31, and 32 were sacriﬁced after 4 weeks. Mouse
tissues and organs, including liver, thigh muscles, kidney, and spi-
nal cord, were snap frozen in liquid N2 and kept at 70C. For ex-
traction of RNA samples, 0.1 g of mouse tissue was pulverized in
liquid N2 with mortar and pestle, and homogenized with 1 ml of
Trizol (Invitrogen). Total RNA was then isolated according to the
manufacturer’s directions.
Results
ASO Walk along the Proximal Intronic
Regions Flanking Exon 7
Positive or negative signals, including ISSs residing up-
stream of a 30 splice site or downstream of a 50 splice site,Thecan strongly affect exon recognition. To identify potential
ISSs that inhibit SMN2 exon 7 inclusion, we systematically
screened 60 nt of intronic sequences on either side of exon
7. We used 15-mer 20-O-methoxyethyl ribose (MOE)-mod-
iﬁed phosphodiester ASOs, with 10 ASOs targeting each
ﬂanking intronic region. Neighboring ASOs overlapped
by 10 nt (Figure 1, Table 1). ASOs with the MOE modiﬁca-
tion throughout show nuclease resistance, enhanced afﬁn-
ity for hybridization to complementary RNA, and do not
support cleavage of the target mRNA by RNase H;44 this
class of compound is highly effective at modifying gene ex-
pression by binding to RNA and modifying pre-mRNA
splicing patterns.44
We ﬁrst tested each ASO by using a cell-free splicing
assay with a radiolabeled SMN2 minigene transcript (Fig-
ure 2A).6,30 Two hundred nanomolar of each ASO was
included in a standard in vitro splicing reaction.42 The
SMN1 minigene transcript without ASO treatment was
used as a positive control for exon inclusion, and treat-
ment with an unrelated oligonucleotide, 00–00, was used
as a negative control. Compared with the negative control,
addition of ASO 55–41 or either of two overlapping ASOs,
11–25 and 16–30, led to a pronounced increase in exon 7
inclusion, with 11–25 giving the strongest effect. These re-
sults suggest the existence of two ISSs: one in intron 6 and
one in intron 7. ASO 55–41, which is complementary to
nt 41 to 55 of intron 6, nearly doubled the extent of
exon 7 inclusion. ASO 16–30, whose target overlaps by
10 nt with that of ASO 11–25, was less effective than 11–
25, suggesting that the ISS in intron 7 is located within
or overlapping ASO 11–250s target sequences. As expected,
four ASOs (15–01, 20–06, 25–10, and 30–16) that target the
30 splice site, polypyrimidine tract, or branch point se-
quence in intron 645 strongly inhibited exon 7 inclusion.
ASO 01–15 also strongly inhibited exon 7 inclusion, and
Figure 1. Schematic Representation of the Binding Sites for
the 20 MOE ASOs Used in the Initial ASO Walk along the Two
Flanking Intronic Regions of Exon 7
(A) ASO walk at the end of intron 6.
(B) ASO walk at the beginning of intron 7.
The position of complementarity of each ASO is indicated by a
horizontal line above the sequence.American Journal of Human Genetics 82, 834–848, April 2008 837
Figure 2. Analysis of the 20 MOE ASOs
by Splicing In Vitro and in Cells
The diagrams on the right indicate the
mobilities of the various RNA species. The
percentage of exon 7 inclusion in each
lane was calculated as described in Material
and Methods and is indicated below each
phosphorimage diagram. For the two
in vivo splicing assays, each ASO at a con-
centration of 10 mM and 2 mg of pBabe-
Puro was cotransfected with or without
pEGFP-SMN2 into HEK293 cells. Two days
after transfection, cells were collected for
total RNA extraction, and RT-PCR was per-
formed for the analysis of SMN2 pre-mRNA
splicing patterns.
(A) Each ASO at a concentration of 200 nM
was tested by in vitro splicing with an
SMN2 minigene substrate. ASO 00–00 was
used as a negative control, and SMN1 was
used as a positive control. The radiolabeled
RNAs were analyzed by 8% denaturing
PAGE.
(B) The 20 ASOs were cotransfected with
a pEGFP-SMN2 minigene, and RT-PCR prod-
ucts were analyzed by 8% native PAGE.
(C) The effects of the 20 ASOs were
analyzed with transcripts from the endoge-
nous SMN2 gene in HEK293 cells. RT-PCR
products were digested with DdeI so that
SMN1 could be distinguished from SMN2
by 6% native PAGE. FL indicates full-
length, and D7 indicates exon 7 deleted
mRNA.we presume that it competes with U1 snRNA for binding to
the 50 splice site of intron 7.
To further examine the effects of individual ASOs on
exon 7 inclusion, we measured splicing of SMN2minigene
transcripts, as well as endogenous transcripts, in HEK293
cells.30 We cotransfected the minigene plasmid pEGFP-
SMN2 with pBabe-Puro and each of the 20 MOE ASOs by
electroporation. pEGFP-SMN2 was chosen because it gives
more pronounced exon 7 skipping as compared to pCI-
SMN2,30 and therefore the effects of ASOs on exon 7 inclu-
sion canbemore readily observed. Transfected cellswere se-
lected with puromycin.30 Two days after transfection, both
the transiently expressedmRNA (Figure 2B) and the endog-
enous SMN2 mRNA (Figure 2C) were analyzed by RT-PCR
with appropriate primers. For the endogenous transcripts,
SMN1 and SMN2 spliced mRNAs can be distinguished
from each other after digestion with DdeI.46,47 Both mini-
gene and endogenous-gene assays gave results consistent
with those obtained by cell-free splicing (Figure 2A). We
also observed that the ASOs affected the endogenous
SMN1 transcripts, in addition to the SMN2 transcripts.
In summary, the ASO tiling through the two intronic
ﬂanks of exon 7, in combination with three different splic-
ing assays, identiﬁedonemoderate ISS andone strong ISS in
intron6 and intron7, respectively. Blocking the intron7 ISS838 The American Journal of Human Genetics 82, 834–848, April 20in SMN2 pre-mRNA promoted exon 7 inclusion to a level
comparable to that of the SMN1 pre-mRNA, and therefore,
ASO 11–25 has considerable therapeutic potential.
Two Motifs within the Intron 7 ISS Region
Mediate Repression of Exon 7 Inclusion
ASO 11–25 displayed the strongest stimulatory effect on
exon 7 inclusion, indicating that its target harbors at least
one inhibitory cis-element. To determine the mechanism
underlying repression, we introduced a series of mutations
within and surrounding the ASO-target region, in the con-
text of the pCI-SMN2 minigene plasmid (Figure 3A). Be-
cause this region is purine rich and C poor, we individually
mutated all As, Gs, and Us into Cs and all Cs into Us. Each
plasmid was electroporated into HEK293 cells, and the
transiently expressed mRNAs were analyzed by RT-PCR.
Two AG dinucleotides (þ12 to þ13 and þ23 to þ24)
proved to be critical for silencing: Each of the mutations
in these four nucleotides (A12C, G13C, A23C, and
G24C) markedly increased exon 7 inclusion compared to
the parental (WT) SMN2 minigene (Figure 3B). A21C also
noticeably increased exon 7 inclusion (Figure 3B). Interest-
ingly, mutant C11U, which creates a match to the UAG
core (þ11 to þ13) of the hnRNP A1 consensus motif,48–50
further inhibited exon 7 inclusion.08
To verify that the two AG dinucleotides are important for
silencing—as opposed to the mutations fortuitously creat-
ing positive elements—we generated additional mutants
that disrupt one or both AG dinucleotides: single mutants
A12U, G13U, A23U, and G23U; double mutant 2A-2C
(A12C þ A23C); single-deletion mutants D12A, D13G,
DAG1st (deleting the 12A,13G dinucleotide), D23A, D24G,
DAG2nd (deleting the 23A,24G dinucleotide); and double-
deletion mutant D2AGs (deleting both AG dinucleotides).
All of these mutants gave pronounced increases in exon 7
inclusion, and in particular, the two substitution or dele-
tion mutants that target both sites simultaneously (2A-2C
and D2AGs) resulted in more than 80% exon 7 inclusion.
Considering that a hexamer or heptamer sequence is gener-
ally sufﬁcient for binding one splicing-repressor mole-
Figure 3. Effects of Mutations in and
around the Intron 7 ISS on SMN2 Exon
7 Inclusion
(A and C) WT and mutant intron 7 se-
quences. Mutations are shaded, and dele-
tions are indicated by dashes.
(B and D) WT pCI-SMN2 and mutant mini-
gene plasmids (5 mg) were electroporated
into HEK293 cells. Total RNA was collected
two days after transfection and analyzed by
radioactive RT-PCR. The radiolabeled PCR
products were analyzed by 8% native
PAGE and detected and quantitated with
a phosphorimager.
cule,51 these data suggest the exis-
tence of two separate motifs within
the intron 7 ISS, each encompassing
one of the AG dinucleotides that are
separated by nine nucleotides. We
refer to the upstream motif in the
silencer as motif 1, and to the down-
stream one as motif 2. The increase
in exon 7 inclusion in the double-sub-
stitution 2A-2Cmutant or the double-
deletion D2AGs mutant is approxi-
mately the sum of the effects of the
two single-substitution A12C and
A23C mutants or of the single-dele-
tion DAG1st and DAG2nd mutants, re-
spectively (Figure 3), suggesting an
additive effect rather than a synergis-
tic effect of the twomotifs on splicing
repression.
The Intron 7 ISS Is Bound
Speciﬁcally by hnRNP A1 and A2
The two critical AG dinucletides in
the intron 7 ISS provide a hint about
the identity of the repressor(s) be-
cause previous reports demonstrated
that an AG dinucleotide is critical for hnRNPA1 high-afﬁn-
ity binding.49,50,52 On the basis of our mutagenesis analy-
sis, we hypothesized that the two AG dinucleotides are part
of two weak hnRNPA1 binding motifs that, owing to their
close juxtaposition, make up a strong hnRNP A1 binding
element. To test our hypothesis, we conducted RNA-afﬁn-
ity chromatography.43 A WT 16-mer intron 7 RNA frag-
ment (þ10 to þ25) comprising the two potential weak
hnRNP A1 motifs was covalently linked to agarose beads
via the 30 end,43 and incubation with HeLa cell nuclear ex-
tract followed. Three mutant RNAs (A12C, A23C, and 2A-
2C) were used as controls. Proteins that remained tightly
bound to each RNA after washing at two different salt con-
centrations (150 mM and 300 mM) were analyzed by SDS-
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blotting (Figure 4). Two strong bands (34 kDa and 36 kDa)
were observed in the WT RNA sample by Coomassie-blue
staining, and the corresponding bands were weaker with
the mutant RNA samples, especially the double mutant.
In particular, after the beads were washed in 300 mM
KCl, the two bands disappeared in the case of the 2A-2C
double-mutant RNA, in which both AG dinucleotides
were mutated. These data indicate that both proteins spe-
ciﬁcally bind the intron 7 ISS, and the binding is depen-
dent on the two potential hnRNP A1 motifs. The lower
band has the expected mobility of hnRNP A1, whereas
the upper band could be the 36 kDa hnRNP A2 protein,
a closely related hnRNP A/B family member with similar
effects on SMN2 exon 7 splicing regulation as hnRNP
A1.7,32,53
To verify the identity of the two proteins isolated
by RNA-afﬁnity pulldown, we used three different mono-
clonal antibodies: A1/UP1-55 recognizes only hnRNP A1;
DP3B3 recognizes hnRNP A2 and its lower-abundance
isoform hnRNP B1 (~38 kDa); and A1/UP1-62 recognizes
all the hnRNP A/B family proteins (Figure 4C). Western
blotting clearly showed that the two prominent bands
are hnRNPA1 and A2, respectively, and also that the other
hnRNPA/B family proteins likewise bind speciﬁcally to the
silencer. hnRNP B1, A1B, and A3 were not as prominent as
A1 and A2 in the pulldown material (Figure 4B), but this
may simply reﬂect their lower abundance in HeLa cell
nuclear extract (Figure 4C). These data demonstrate that
the intron 7 ISS is recognized speciﬁcally by hnRNP A/B
proteins, in particular the abundant hnRNP A1 and A2.
Other RNA-binding proteins also interacted strongly with
the intron 7 RNA fragment, especially a band of approxi-
mately 75 kDa (Figure 4B); however, this and other pro-
teins appeared to interact nonspeciﬁcally, showing no
difference in binding between the WT and all mutant
RNAs.
hnRNP A/B family proteins are a group of structurally
and functionally similar proteins. In particular, hnRNP
A1 and A2 are both abundantly expressed, share approxi-
mately 70% amino acid sequence identity, and inhibit
both 50 and 30 splice-site recognition, or promote distal
50 splice site selection while suppressing proximal splice
site use.53 Several studies showed that hnRNPA2 also binds
hnRNP-A1-speciﬁc motifs,43,54,55 so it is not surprising that
we pulled down both proteins with RNA-afﬁnity chroma-
tography. The UAG motif has been widely described as a
critical core of the hnRNP A1 binding motif;43,48,50,56–58
however, CAG has also been found in SELEX winner se-
quences,49 and especially with equilibrium-binding assays,
multiple sequences that contain one or two CAG motifs
but no UAG motif have been demonstrated to have strong
binding afﬁnity for hnRNPA1.52 It is likely that CAG repre-
sents the core of a suboptimal hnRNP A1 binding element
in themotif 1 region; this ﬁts with the observation that the
mutant C11U, which improves the match to the consen-
sus, displayed stronger inhibition of exon 7 inclusion (Fig-
ure 3). In themotif 2 region, themutant A22C strongly pro-840 The American Journal of Human Genetics 82, 834–848, April 20moted exon 7 skipping, suggesting that CAG (þ22 to þ24
in mutant A22C) is a stronger motif than AAG in this
context for recognition by hnRNP A1/A2. Because 21A in
the motif 2 region is also important, it appears that
AAAG (þ21 to þ24) forms another core of a weak hnRNP
A1/A2 binding site in the context of the SMN2 intron 7
ISS. In agreement with our result, the 30 splice site of adeno-
virus type 2 exon 1a, which has an AAAGmotif but neither
UAGnor CAGmotifs, binds hnRNPA1.52We conclude that
Figure 4. Analysis of Proteins Bound to the Intron 7 ISS by
RNA-Affinity Chromatography
(A) Four RNA oligonucleotides corresponding to the WT and three
mutant sequences shown were used for RNA-affinity chromato-
graphy.
(B) Agarose beads covalently linked to the RNAs shown in (A) were
incubated with HeLa cell nuclear extract under splicing conditions,
and the beads were washed three times at the indicated salt con-
centrations. Bound proteins were eluted with SDS and analyzed by
SDS-PAGE with Coomassie-Blue staining. The migration of size
markers and hnRNP A1 and A2 are indicated.
(C) Western-blotting analysis of the eluted proteins with monoclo-
nal antibodies that recognize only hnRNP A2 and B1 (top), hnRNP
A1 (middle), and all the hnRNP A/B family proteins (bottom); HeLa
cell nuclear extract (NE) was also analyzed for the determination of
the relative signals of the various hnRNP A/B family proteins in the
starting material (bottom left).08
Figure 5. Effects of hnRNP A1 or A2
Overexpression on Exon 7 Inclusion in
SMN1 Minigene Transcripts
HEK293 cells were transfected with 5 mg of
the indicated WT or mutant pCI-SMN1 plas-
mids (described in Figures 3A and 3C).
The indicated amounts of pCGT7-A1 (A)
or pCGT7-A2 (B) expressing N-terminal
T7-tagged hnRNP A1 or A2 proteins were
cotransfected with the SMN1 reporters.
Two days after transfection, total RNA
was collected and radioactive RT-PCR was
performed to measure the extent of exon
7 inclusion by 8% native PAGE and phos-
phorimage analysis. The expression of
tagged hnRNP A1 or A2 was verified by
western blotting with monoclonal antibody
against the T7 tag. The histograms on the
right show the corresponding quantitation
from three independent experiments. Error
bars represent the standard deviation.the minimal size of the intron 7 ISS is CAGCTTATGAAAG
(þ11 to þ 24), with one hnRNP A1 motif (CAG) at the 50
end, and another one (AAAG) at the 30 end.
Effects of hnRNP A1/A2 Overexpression
Having shown direct binding of hnRNP A1/A2 to the
intron 7 ISS, we next tested the prediction that overexpres-
sion of hnRNP A1/A2 should lead to stronger inhibition
of exon 7 inclusion via the speciﬁc intron 7 hnRNP A1 si-
lencer. In fact, previous work demonstrated that overex-
pression of hnRNP A1 does inhibit exon 7 inclusion for
both endogenous SMN1 and SMN2 genes, suggesting the
existence of a shared hnRNP-A1-dependent ESS or ISS,
though its location remained unknown.7 To examine the
interplay between hnRNP A1/A2 overexpression and the
intron 7 ISS, we analyzed three of the above mutants,
A12C, A23C, and 2A-2C, in the SMN1-minigene context,
and compared them to the WT SMN1 minigene; the ﬁrst
two mutants disrupt the ﬁrst and second motif, respec-
tively, and the third mutant disrupts both motifs. We
used an SMN1minigene rather than an SMN2minigene be-
cause we wanted to minimize the potential inﬂuence of
other hnRNP A1 binding sites. So far, no hnRNP A1 bind-
ing sites have been mapped in SMN1, whereas two such
sites have been reported to be present in SMN2.15,32,33
Each mutant or WT SMN1 minigene plasmid, together
with an hnRNP A1 or A2 expression plasmid, was electro-
porated into HEK293 cells, and RNA and protein samples
extracted after 48 hr were used for RT-PCR and western-
blot assays. Both hnRNPA1 and A2 plasmids express N-ter-
minal T7-tagged proteins to facilitate detection. As shown
in Figure 5, when transfected alone, each of the mutantTheandWT SMN1minigenes gave a similar extent of exon 7 in-
clusion; in contrast, when 3 mg of hnRNP A1 plasmid was
cotransfected with these minigenes, exon 7 inclusion was
reduced to 35% for the WT SMN1 minigene and to 82%
for the 2A-2C double mutant, with the A12C and A23C
single mutants giving intermediate reductions in exon 7
inclusion (52% and 62%, respectively).
When 3 mg of hnRNP A2 plasmid was cotransfected, we
observed slightly weaker but otherwise similar inhibitory
effects for all the WT and mutant minigenes (Figure 5B).
These data indicate that the inhibitory effects of hnRNP
A1/A2 depend on the intron 7 ISS, and the greater sensitiv-
ity of the WT SMN1 minigene to these repressors reﬂects
the presence of the two tandem hnRNP A1/A2 motifs.
Interestingly, we reproducibly observed that hnRNP A1
overexpression had a stronger inhibitory effect with the
A12C mutant than with the A23C mutant, whereas
hnRNP A2 overexpression gave the opposite pattern, sug-
gesting that these two closely related repressors are not
completely identical in how they recognize and bind to
RNA.
Improvement of hnRNP A1/A2 Motifs
and Consequences for Exon 7 Splicing
Having shown that disruption of the weak, tandem hnRNP
A1/A2motifs in the intron 7 ISS abrogates the repression of
exon 7 inclusion, we next asked whether improving these
two motifs by mutagenesis results in a greater extent of
exon 7 skipping (Figure 6). In the motif 1 region, C11U,
which should improve hnRNP A1 binding, was already
described above (Figures 3A and 3B). We generated three
additional mutants of the SMN2 minigene within theAmerican Journal of Human Genetics 82, 834–848, April 2008 841
Figure 6. Effect of Improving the
hnRNP A1/A2 Motifs in the Intron 7
ISS on Exon 7 Splicing
(A) Sequences of the WT intron 7 ISS and
mutants with improved hnRNP A1/A2 mo-
tifs. The hnRNP A1/A2 motifs are under-
lined. Single mutations are shaded.
(B and C) RT-PCR analysis showing the
effects of improving the hnRNP A1/A2 mo-
tifs in either the motif 1 or motif 2 region.
Mutants were tested in both SMN2 and
SMN1 minigene contexts. Five micrograms
of WT pCI-SMN2, pCI-SMN1, or each mutant
plasmid was transfected into HEK293 cells
by electroporation. Total RNA was ex-
tracted 2 days later and analyzed by radio-
active RT-PCR and then 8% native PAGE
and phosphorimage quantitation.
(D) Quantitative data of mutagenesis anal-
ysis, including previous experiments (Fig-
ure 2), are presented as a scatter plot.
The percentage of exon 7 inclusion was
plotted against hnRNP A1 scores based on
a PWM with background correction for the
base composition of the winner pool.7
Data points for mutants in the motif 1
and motif 2 regions are shown as open cir-
cles and solid squares, respectively. Least-
squares lines are shown for each data set
(dashed line for motif 1 with R2 ¼ 0.75,
and solid line for motif 2 with R2 ¼ 0.61).motif 1 region: C14G, winner 1(1), and winner 2(1). Win-
ner 1(1) replaces the WT sequence CAGCAU (þ11 to þ16)
with an hnRNP A1 winner sequence, UAGGGU;49 winner
2(1) replaces the same 6 nt sequence with UAGGUC,
which is thought to be recognized by RRM2 of hnRNP
A149 and is a strong functional hnRNP A1-responsive
element (H.O. and A.R.K, unpublished data). In the motif
2 region, we also generated four mutants expected to
improve hnRNP A1 binding: A22U, U25G, winner 1(2),
and winner 2(2). A22U creates a UAG-containing motif
(þ22 to þ27), but the motif is shifted 3 nt downstream
of the original UGAAAG (þ19 to þ24) motif. U25A creates
a hexamer AAGGGA (þ22 to þ27) that is also shifted 3 nt
downstream. All of these seven mutants in the context
of the SMN2 minigene displayed greater inhibition of
exon 7 inclusion than the parental construct, with the per-
centage of inclusion ranging from 3% to 37%, compared to
46% for the WT SMN2 minigene (Figure 6B). We also gen-
erated these sevenmutants, plus mutant C11U, in the con-
text of the SMN1 minigene and observed similar, though,
as expected, less pronounced, effects on inhibition of
exon 7 inclusion than in the SMN2minigene context (Fig-
ure 6C). The inhibitory effects were stronger when the
same motifs were placed in the motif 1 region than in the
motif 2 region, perhaps reﬂecting the shorter distance of
motif 1 to the 50 splice site. Interestingly, the winner 2 se-
quence UAGGUC resulted in greater inhibition than the
winner 1 sequence UAGGGU when placed in the motif 1842 The American Journal of Human Genetics 82, 834–848, April 20region, whereas the relative effects were reversed in the
context of the motif 2 region, pointing to the contribution
of position and/or context in the activity of each motif.
To analyze the correlation between hnRNP A1 motif
scores of the various wild-type and mutant sequences
and their effects on exon 7 inclusion, we took advantage
of an hnRNP A1 position weight matrix (PWM) with back-
ground correction (A1_winBG), which was previously
derived from SELEX data.7,49 The percentage of exon 7 in-
clusion in the SMN2minigene context was plotted against
the calculated hnRNP A1 scores. Because the same motifs
had different effects on exon 7 splicing when they were
placed in the motif 1 region versus the motif 2 region (Fig-
ures 6B and 6C), we provide both datasets (Figure 6D). We
observed a strong negative correlation between the extent
of exon 7 inclusion of the SMN2 minigene mutants and
the corresponding motif scores: The coefﬁcient of determi-
nation (R2) is 0.75 for motif 1 and 0.61 for motif 2. Note
that because this PWM is based on hnRNP A1 SELEX
winners,49 the scores of weak motifs with an AAAG core
are generally negative, whereas the scores of weak motifs
with a CAG core can be negative or positive depending
on the number of nucleotide matches to the consensus
hexamer.
Correction of SMN2 Splicing in Transgenic Mice
After elucidating the exact position and mechanism of the
intron 7 ISS, we optimized the most potent ASOs that08
target this silencer and used them to try to rescue SMN2
splicing in mice harboring a human SMN2 transgene. First,
we synthesized 38 ASOs of different lengths and examined
their effects on splicing of transcripts of the endogenous
SMN2 gene in HEK293 cells. The results are summarized
in Figure 7. Four 18-mer ASOs displayed the strongest ef-
fects, with ASO 10–27 being slightly better than the other
three (08–25, 09–26, and 11–28). The most effective 15-
mer was ASO 09–23, which was slightly better than ASOs
10–24 and 11–25; the best 12-mer was ASO 10–21, though
it was considerably weaker than the 15-mer ASO 09–23.
We also examined ASOs 10–27 and 09–23 in SMA type I pa-
tient 3813 ﬁbroblasts and found that both ASOs were more
efﬁcient in promoting SMN2 exon 7 splicing and increas-
ing SMN protein levels compared with our best two ASOs
targeting exon 7 (Figure S1 available online).30
On the basis of these results in cultured cells, we selected
ASOs 10–27 and 09–23 for further work in mice. These
ASOs were resynthesized on a larger scale and with a
phosphorothioate backbone instead of a phosphodiester
backbone, for improved in vivo stability and pharmacoki-
netics.59 Recipient adult mice of both sexes were trans-
genic for hSMN2 and hemizygote or WT at the mouse
Smn locus.60 ASOs were dissolved in saline and delivered
intravenously, twice a week, at 25 mg/kg. Each ASO was
administered to eight mice, and tissues and organs were
harvested after 1, 2, 3, or 4 weeks of treatment (two mice
each). As controls, eight mice received saline only, and
another eight mice received a 15-mer scrambled-sequence
oligonucleotide, ASO 00–00 (Table 1).
We ﬁrst analyzed splicing changes of hSMN2 transcripts
by RT-PCR with a pair of human-speciﬁc primers, with
total RNA from liver, skeletal muscle (thigh), kidney, and
spinal cord (Figure 8). No increase in exon 7 inclusion
was observed after treatment with saline or control ASO
00–00 in any of the tissues. However, we observed a striking
Figure 7. Schematic Diagram of the
In Vivo Effects of All Tested Intronic ASOs
Horizontal bars represent ASOs with stimu-
latory effects (green), inhibitory effects
(red), or neutral effects (blue). The thicker
the bars, the stronger the effects.
(A) ASOs targeting the 30 region of intron 6.
(B)ASOs targeting the 50 region of intron 7.
* indicates the four 18-mer ASOs (08–25,
09–26, 10–27, and 11–28) that displayed
the strongest stimulatory effects. # indi-
cates the best 15-mer ASO (09–23) and
the best 18-mer ASO (10–27) that were
tested in hSMN2 transgenic mice (Figure 8).
increase in exon 7 inclusion in liver
samples from mice treated with ASOs
10–27 or 09–23 (Figure 8A). Exon 7 in-
clusion increased from approximately
21% (the average of all saline- and control-ASO-treated
mice) to approximately 45% in the livers of mice treated
with ASO 09–23 after 1 week administration, and the rate
increased to approximately 69% after 2 week treatment,
to approximately 83% after 3 week treatment, and to ap-
proximately 91% after 4 week treatment. We also
detected a greater than 3-fold increase in exon 7 inclusion
in kidney, and an approximately 2-fold increase in muscle
samples after 3–4 weeks of treatment, though the effects
were not as striking as in liver (Figures 8B and 8C). In
contrast, we did not observe any increase in hSMN2 exon
7 inclusion in spinal cord (Figure 8D); this was expected,
because these ASOs do not penetrate the blood-brain
barrier (BBB).61 These data demonstrate that suitable
ASOs, when delivered to mouse tissues, are able to correct
the splicing defect of the hSMN2 gene transcripts, indicat-
ing that these ASOs have excellent therapeutic potential
for SMA.
Discussion
Correction of SMN2 exon 7 splicing is an attractive thera-
peutic approach for SMA because this gene is present in
all patients, its exon 7 codes for the correct SMN C-termi-
nal peptide, and there are several ways in which inclusion
of this alternative exon can be increased.62 Strategies to
promote SMN2 exon 7 inclusion have included cell-based
screens for small molecules,63 as well as targeted methods,
such as ESSENCE, TOES, and SMaRT.64–66 Antisense tech-
nology, which is traditionally used to inhibit gene expres-
sion,67 can also be used to modulate pre-mRNA splicing by
targeting splice sites or positive or negative elements that
affect splice-site selection.30,35,36,38,68–70 In particular, sys-
tematic screening for splicing silencers that can be blocked
with ASOs is a practical and efﬁcient approach to rescueThe American Journal of Human Genetics 82, 834–848, April 2008 843
Figure 8. Effects of ASOs 09–23 and 10–27 in hSMN2 Transgenic Mice
ASOs 09–23, 10–27, control ASO 00–00, or saline was delivered intravenously via the tail vein, twice a week, at 25 mg/kg. Each ASO or
saline was administered to eight mice, and tissues and organs including liver (A), kidney (B), thigh muscles (C) and spinal cord (D) were
harvested after 1, 2, 3, or 4 weeks of treatment (two mice each). Total RNA was extracted from tissues with Trizol reagent, and RT-PCR was
carried out with a set of hSMN2-specific primers. Radiolabeled PCR products were analyzed by 8% native PAGE and phosphorimaging. The
histograms on the right show the corresponding quantitation. Error bars show standard deviations.certain splicing defects. Recently, we used this approach to
identify two potential ESSs in SMN2 exon 7 that can be tar-
geted to restore SMN2 exon 7 inclusion.30 Here, we used an
analogous ASO-tiling method to systematically map ele-
ments within the exon-7-proximal upstream intron 6844 The American Journal of Human Genetics 82, 834–848, April 20and downstream intron 7 sequences, pinpointing the pres-
ence of an ISS in each intron. To optimize the length and
position of ASOs targeting the intron 7 ISS, which appears
to be more potent, we carried out high-resolution tiling in
conjunction with cell-based splicing assays. Finally, ASO08
administration to hSMN2 transgenic mice demonstrated
that the optimal ASOs can restore SMN2 exon 7 splicing
to a level similar to that of the human endogenous SMN1
gene—about 90% of exon 7 inclusion.60 These data dem-
onstrate that ASOs targeting the intron 7 ISS have signiﬁ-
cant therapeutic potential.
The intron 7 ISS was recently described and shown to
be effective in a heterologous gene context;36 the 15 nt el-
ement, dubbed ISS-N1, was further shown to gradually lose
its effectiveness whenmoved farther downstream from the
50 splice site. 20-O-methyl-modiﬁed ASOs targeting this ISS
were shown to correct the SMN2 splicing defect in SMA-
patient ﬁbroblasts, increasing SMN protein levels in these
cells.36 However, the underlying repression mechanism
remained to be deﬁned. Here, by using mutagenesis cou-
pled with cell-based splicing assays, RNA-afﬁnity chroma-
tography, and cDNA overexpression, we demonstrated
that splicing repression via the intron 7 ISS is mediated
by hnRNP A1 and A2. The ISS not only physically binds
hnRNP A1 and the structurally and functionally related
protein hnRNPA2, but we further show that it functionally
responds to hnRNPA1/A2 protein levels in cells. Although
there is a putative hairpin in this region, analysis of muta-
tions that would disrupt or restore the predicted secondary
structure failed to uncover any effect (Figure S2).
Pre-mRNA splicing requires the accurate recognition of
50 and 30 splice sites. hnRNP A/B family proteins can affect
both 50 and 30 splice-site selection, in part by antagonizing
splicing activators.71 Two potential SMN2-speciﬁc hnRNP
A1binding siteshavebeenreported,15,32whereasnohnRNP
A1 binding sites had been identiﬁed that repress exon 7
splicing in the context of SMN1. However, knockdown of
hnRNP A1 and/or A2 promotes exon 7 inclusion for both
SMN2 and SMN1.7,32 In addition, overexpression of hnRNP
A1 in cells inhibits both SMN1 and SMN2 exon7 inclusion.7
These observations suggested the existence of one or more
additional hnRNP A1/A2 binding sites present in both
SMN1 and SMN2. By using RNA-afﬁnity chromatography,
we show that an RNA fragment comprising the intron
7 ISS (þ10 to þ25) is bound strongly and speciﬁcally by
hnRNP A1 and A2. This region encompasses two weak
hnRNP A1 motifs; two single mutations, A12C and A23C,
that disrupt either the ﬁrst or the second motif reduced
the binding of hnRNP A1/A2; and simultaneous mutation
of both motifs virtually abrogated binding. The binding of
hnRNP A1/A2 to the ISS and its mutants correlated well
with the extent of exon 7 skipping in transient transfection
experiments. Thus, our data suggest that two juxtaposed
weak hnRNP A1/A2 binding sites act additively to form a
strong inhibitory element, especially when located near a
splice site.
The intron 7 ISS (ISS-N1) was recently reported to com-
prise nucleotides þ10 to þ24 (CCAGCATTATGAAAG)36.
Our antisense and mutational analyses further sharpen
the boundaries of the silencer region (þ11 to þ24) and
establish its constituent motifs. The ﬁrst hnRNP A1 motif
in the element is CAGCAT (þ11 to þ16), with the core se-Thequence being CAG. Generally, UAG represents a common
hnRNPA1motif core;58,72 however, CAG has also been fre-
quently observed in high-afﬁnity sites identiﬁed by SELEX,
and/or characterized in equilibrium-binding assays.49,52
The second motif, TGAAAG (þ19 to þ24), represents
a new weak hnRNP A1 motif, with the core nucleotides
beingAAAG. It has been previously reported that the AGdi-
nucleotide is the only shared feature among various
sequences with high afﬁnity for hnRNP A1,52 suggesting
that the AG dinucleotide is critical for hnRNP A1 recogni-
tion,whereas the individual contributions of the remaining
nucleotides of the motif might be context dependent. This
notion is consistent with our observation with both SMN2
and SMN1minigenes that, whenwe replaced the two natu-
ral hnRNPA1 ISS motifs with two SELEX winner hexamers
(winner 1: UAGGGU; winner 2: UAGGUC), winner 2 was
stronger than winner 1 when placed in the motif 1 region
but weaker when placed in the motif 2 region (Figure 6).
The two juxtaposed weak hnRNP A1 motifs make up
a strong ISS, illustrating a novel strong splicing silencer
pattern: the combination of two or more tandem weak re-
pressor motifs. This type of splicing silencer, which binds
two or more repressor molecules and spans at least 14 nt,
is unlikely to be captured with previously described com-
putational or cell-based ISS screening methods that
assumed ISS lengths of 6–10 nt, but it may represent a com-
mon group of strong ISSs, especially taking into account
that most 30 splice sites already comprise one copy of
a weak hnRNP A1 motif, such as CAG, or its somewhat
stronger version CAGG.
Cooperative binding and propagation of hnRNP A1
along an exon and its ﬂanking introns has been described
as a mechanism for antagonizing splicing activation by SR
proteins.57,71,73 Therefore, it is reasonable to assume that
either of the two hnRNP A1/A2 molecules that bind
to the intron 7 ISS and hnRNP A1/A2 molecules bound
to other sites, such as the recently reported UAG motif in
SMN2 intron 7,15 result in cumulative spreading of hnRNP
A1/A2 along the SMN2 exon 7 and its ﬂanking intron se-
quences, antagonizing the binding of Tra2-b1, SF2/ASF,
and other splicing factors that are essential for exon 7
recognition.
Previously, two hnRNP A1 molecules were shown to in-
teract simultaneously with two distant high-afﬁnity sites,
such that hnRNP A1 dimerization may loop out segments
of the pre-mRNA, affecting splice-site selection.74 However,
in the context of the SMN2 gene, we have not thus far
observed synergistic effects among different hnRNP A1
motifs (Figures 3 and 5, and Y.H. and A.R.K., unpublished
data), as would have been expected from such a bridging
model. In the cocrystal structure of the UP1 domain of
hnRNP A1 with a 12 nucleotide telomeric single-stranded
DNA (ssDNA), d(TTAGGGTTAGGG), UP1 dimerizes and
RRM1 and RRM2 within the same protein monomer bind
to two separate strands of ssDNA, which are antiparallel.75
Therefore, it is possible that two hnRNP A1 (or A2)
molecules bind to the bipartite intron 7 ISS as a dimer.American Journal of Human Genetics 82, 834–848, April 2008 845
In the present study, we examined hSMN2 exon 7 inclu-
sion in four transgenic mouse tissues after intravenous
administration of ASOs. Liver showed the strongest effects,
kidney gave intermediate effects, and muscle gave weak
effects, whereas spinal cord showed no change in hSMN2
exon 7 inclusion. These tissue-speciﬁc effects are consis-
tent with previous reports that MOE ASOs preferentially
distribute to peripheral tissues, and that hepatocytes spon-
taneously take up these ASOs.61 In addition, the lack of an
effect on spinal cord was expected, because of the BBB.
Because of the presence of mouse SMN protein in these
mice and the high degree of homology between themurine
andhuman proteins, it is difﬁcult to verify that the increase
in full-length mRNA translates into an increase in trans-
genic SMN protein. The Smn null transgenic mice survive
for only a few days in this model,60 which is incompatible
with our current delivery protocol. We and others previ-
ously showed that ASO-induced increases in full-length
hSMN2 mRNA result in increased SMN protein levels, at
least in cell culture.30,36 In the future, it may be possible
tomeasure the expected increase in transgenic SMNprotein
levels in mouse tissues with a suitable human SMN anti-
body that does not crossreact with the murine protein.
In the context of SMA therapy, these ASOs will either
have to be directly administered to the CNS or methods
will have to be developed to allow them to efﬁciently pene-
trate the BBB. As an example of the ﬁrst approach, in recent
studies of amyotrophic lateral sclerosis (ALS), an MOE ASO
designed to inactivate dominant-negative mutant SOD1
transcripts was directly delivered to the CNS of an ALS rat
model; spinal-cordmotor neurons spontaneously internal-
ized theASO, resulting in knockdownof themutant gene.76
Illustrative of the second approach, a 29 amino acid peptide
derived from rabies-virus glycoprotein was recently used to
facilitate delivery of small interfering RNA (siRNA) across
the BBB in mice.77 We plan to explore similar approaches
to deliver ASOs that correct hSMN2 exon 7 splicing into
transgenic mouse spinal-cord motor neurons.
Supplemental Data
Two ﬁgures are available at http://www.ajhg.org/.
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